Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2008

View Archived Issues

Inositol hexaphosphate reduces cellular growth of bladder cancer in vitro

Selective inhibitor of human tryptase shows benefit in models of asthma and rhinitis

LASSBio-596 active in mouse model of silicosis

CCR4 antagonist K-327, potentially useful in allergic airways inflammation

Novartis launches Tasigna in the U.K. for Philadelphia chromosome-positive CML

ImmuneRegen announces preliminary results from dermatological testing of Homspera

ImmuPharma reports preclinical data on nucleolin antagonist peptide IPP-204106

Palatin initiates dosing in phase IIa clinical study of PL-3994 for hypertension

SWOG initiates enrollment in phase I clinical trial of ImClone Systems' IMC-A12

KAI Pharmaceuticals initiates enrollment in phase I clinical study of KAI-1678

Ceragenix announces results from comparison study of EpiCeram cream in pediatric AD

Alizyme commences phase II Colal-Pred study in the U.S.

BioAlliance acquires European rights to ondansetron oral spray

Bone Medical receives FDA confirmation for Capsitonin clinical trial strategy

Denosumab study meets primary and secondary bone mineral density endpoints

Sangart completes enrollment in second phase III Hemospan study

Transgene presents promising phase I preliminary results of its HCV vaccine

VGX files two separate INDs for novel cervical cancer and avian flu DNA vaccines

FDA approves Entereg for management of postoperative ileus

Recent Wyeth and Takeda patents disclose novel antipsychotic and antidepressant agents

Recent Fujifilm and AstraZeneca patents describe new diagnostic agents

New antibacterial agents reported in recent Novartis patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...